ERBB2 and breast cancer: The reasons for these discordant results between phase III trials are not fully understood, and the results of other first-line studies incorporating ICB in association with standard of care are eagerly awaited (e.g., the IMpassion 132 trial NCT03371017 in mTNBC, or NCT03199885 in HER2+ BC).